Therefore, more sophisticated genetic tools and targeting strategies as well as more advanced cell-based model systems (e.g., patient-derived xenografts, organoids, refs. [101,102]) should be used in the future to dissect the molecular functions of MALAT1 and NEAT1 in pancreatic cancer. This evidence concerns the gene MALAT1 and familial pancreatic carcinoma.